ArticleAmerican journal of cancer research2020

KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.

Xiaoshan Zhang et al.PubMed ↗Full text ↗

No numbers read from the abstract.